Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4002127 | 0.86 | OPRM1 (0.41) | SMN1; SMN2CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL31128631 | 0.85 | AR (0.38) | ARSMN1; SMN2F2CYP1A2CYP3A4 | |
| SCHEMBL2058368 | 0.84 | L3MBTL1 (0.42) | ARSMN1; SMN2RAB9AL3MBTL1ADAMTS5 | |
| SCHEMBL4002061 | 0.75 | ALDH1A1 (0.47) | RAB9AOPRL1OPRM1HTTPOLB | |
| SCHEMBL12646885 | 0.74 | AR (0.45) | ARSMN1; SMN2RAB9AOPRL1OPRM1 | |
| SCHEMBL292131 | 0.72 | AR (0.43) | ARSMN1; SMN2F2CYP1A2CYP3A4 | |
| SCHEMBL4002163 | 0.72 | OPRM1 (0.46) | SMN1; SMN2CYP3A4CYP2C19OPRL1OPRM1 | |
| SCHEMBL21753312 | 0.71 | ITGB3 (0.51) | OPRL1OPRM1 | |
| SCHEMBL2282807 | 0.70 | METAP2 (0.43) | SMN1; SMN2F2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21765220 | 0.69 | OPRL1 (0.45) | SMN1; SMN2RAB9AOPRL1OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791821-B1 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-05 | — | — | EP | claimed |
| CN-101056862-B | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2013-03-13 | — | — | CN | claimed |
| US-7531565-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | claimed |
| CN-101056862-A | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-17 | — | — | CN | claimed |
| EP-1791821-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-06 | — | — | EP | claimed |
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | claimed |
| WO-2006031715-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | claimed |
| EP-1791821-B1 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-05 | — | — | EP | disclosed |
| EP-1791821-B1 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-05 | — | — | EP | disclosed |
| CN-101056862-B | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2013-03-13 | — | — | CN | disclosed |
| US-7968580-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-7968580-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20090215848-A1 | Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS) | LANTER JAMES C | 2009-08-27 | — | — | US | disclosed |
| US-7531565-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531565-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531565-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| CN-101056862-A | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-17 | — | — | CN | disclosed |
| EP-1791821-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-06 | — | — | EP | disclosed |
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | disclosed |
| WO-2006031715-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885SMN1; SMN2 3134/4885F2 4369/4885 |
| US-20090215848-A1 | Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885SMN1; SMN2 3134/4885F2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.